Terms: = Lung cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Prognosis
690 results:
1. Targeting kras in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
2. Drugging the undruggable: Advances in targeting kras signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
4. Targeting kras in cancer.
Singhal A; Li BT; O'Reilly EM
Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
[TBL] [Abstract] [Full Text] [Related]
5. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
[No Abstract] [Full Text] [Related]
7. [Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
[No Abstract] [Full Text] [Related]
8. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with kras G12D mutations in resected lung adenocarcinoma.
Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
[TBL] [Abstract] [Full Text] [Related]
9. STK11/LKB1 alterations worsen the poor prognosis of kras mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
[TBL] [Abstract] [Full Text] [Related]
10. Effects of different kras mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
[TBL] [Abstract] [Full Text] [Related]
11. 2021 WHO Classification of lung cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
[TBL] [Abstract] [Full Text] [Related]
12. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.
Gu Z; Huang P; Zhao J; Luo C; Liao L; Liu A; Huang L
Int J Cancer; 2024 Jun; 154(11):1979-1986. PubMed ID: 38353428
[TBL] [Abstract] [Full Text] [Related]
13. Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in kras
Lin P; Cheng W; Qi X; Zhang P; Xiong J; Li J
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338834
[TBL] [Abstract] [Full Text] [Related]
14. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell lung cancer.
Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
[TBL] [Abstract] [Full Text] [Related]
15. Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma.
Wang D; Huang L; Qian D; Cao Y; Wu X; Xu P; Ming L; Tang J; Huang Z; Yin Y; Zhou L
Front Immunol; 2023; 14():1334408. PubMed ID: 38259481
[TBL] [Abstract] [Full Text] [Related]
16. kras modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinoma.
Li N; Tian Y; Liu X; Pan C; Xue J
Medicine (Baltimore); 2023 Dec; 102(52):e36597. PubMed ID: 38206735
[TBL] [Abstract] [Full Text] [Related]
17. Non-invasive decision support for clinical treatment of non-small cell lung cancer using a multiscale radiomics approach.
Zhang X; Zhang G; Qiu X; Yin J; Tan W; Yin X; Yang H; Wang H; Zhang Y
Radiother Oncol; 2024 Feb; 191():110082. PubMed ID: 38195018
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathological significances of cribriform pattern in lung adenocarcinoma.
Pyo JS; Lee BH; Min KW; Kim NY
Pathol Res Pract; 2024 Jan; 253():155035. PubMed ID: 38171080
[TBL] [Abstract] [Full Text] [Related]
19. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M
J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906
[TBL] [Abstract] [Full Text] [Related]
20. Pan-cancer analysis of homeodomain-containing gene C10 and its carcinogenesis in lung adenocarcinoma.
Tan X; Li Z; Xie H; Chen J; Xiao J; Zhi Y; Mo H; Huang Y; Liu A
Aging (Albany NY); 2023 Dec; 15(24):15243-15266. PubMed ID: 38154103
[TBL] [Abstract] [Full Text] [Related]
[Next]
